Subvalorização das Artralgias: Papel do Enfermeiro na detecção precoce da Imunotoxicidade
Palavras-chave:
Imunoterapia, reações adversasResumo
Os Inibidores do Checkpoint Imunitário (ICI) revolucionaram o tratamento oncológico. Os efeitos adversos da imunoterapia decorrentes da administração dos inibidores do checkpoint imunitário podem ser graves e potencialmente fatais. Embora a maioria das toxicidades seja bem estudada e sobejamente relatada, as complicações reumatológicas são menos reconhecidas e caracterizadas. Descreve-se um estudo de caso em que tanto Performance Status como a qualidade de vida (QdV) de um doente foram afetados pela imunotoxicidade reumatológica bem como o papel do enfermeiro na sua deteção precoce e os cuidados de enfermagem prestados de forma a minimizar o seu impacto na QdV.
Downloads
Referências
Abdel-Wahab, N., Suarez-Almazor, M.E. (2019). Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology, 58, vii40–vii48.
Aranda S, Jefford, M., Yates P, et al (2012). Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial. Ann OncoL, Jan 23(1):222-231.
Benfaremo, D., Manfredi, L., Luchetti, M.M. et al (2018). Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf. 13(3):150-164.
Brahmer, J.R., Lacchetti, C., Schneider, B.J. et al (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology(ASCO) clinical practice guideline. J Clin Oncol, 36:1714–68.
British Geriatrics Society (2017). Fit for Frailty - Consensus best practice guidance for the care of older people living in community and outpatient settings. London, 22p.
Broens, T.H; Huis IN’T Veld, RM; Vollenbroek-Hutten, MM et al (2007). Determinants of successful telemedicine implementations: a literature study. J Telemed Telecare 13(6):303-9.
Butcher, HK; Bulechek , GM; Dochterman, J.M.M., et al (2018). Nursing Interventions Classification (NIC). Elsevier Health Sciences, 7ª edição. 512 pg.
Cappelli, L.C., Gutierrez, A.K., Bingham, C.O., et al (2017). Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res, 69:1751_63.
Champiat, S., Lambotte, O., Barreau, et al (2016). Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol, Apr 27(4):559–74.
Elias, R., Morales, J., Presley, C. (2017). Checkpoint Inhibitors for Non-Small Cell Lung CancerAmong Older Adults. Curr Oncol Rep19:62.
Fabião, A. (2004) Pessoa com doença oncológica: Re(encontro com a qualidade de vida – Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto.
Haanen, J.B.A.G., Carbonnel, F., Robert, C. et al (2017); ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol;28 Suppl 4:iv119–42.
Henderson, V. (2007) Princípios básicos de enfermagem da CIE, 1ª ed., Lusodidacta, Portugal, 92p.
Hurria, A., Mohile, S., Gajra, A. et al. (2016). Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol;34:2366–U104.
Jamal, S., Hudson, M., Fifi-Mah, A. et al (2020) Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol, February, 47 (2) 166-175.
Mcilfatrick, S., Sullivan, K., Mckenna, H. et al (2007). Patients’ experiences of having chemotherapy in a day hospital setting. J Adv Nurs 59(3):264-73.
Mellisaropoulos, K., Klavdianou, K., Filippopoulou, A. et al (2020) - Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors Int J Mol Sci. 21(9):3389.
Mooradian, M.J., Nasrallah, M., Gainor, J.F. et al (2018) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum 48(6):1127-1132.
Noronha, V., Sekhar, A., Vijay, M. et al. (2020). Systemic therapy for limited stage small cell lung carcinoma. J Thorac Dis;12(10):6275-6290.
Paredes, T., Simões, M.R., Canavarro, M.C. et al (2008) - Impacto da Doença Cronica na Qualidade de Vida: comparação entre indivíduos da população geral e doente com tumor no aparelho locomotor. Psicologia, Saúde e Doença, 9 (1), 73-87.
Postow, M.A., Sidlow, R., Hellmann, M.D. (2018). Immunerelated adverse events associated with immune checkpoint blockade. N Engl J Med, 378:158–68.
Steven, N. M. & Fisher, B. A. (2019) - Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective Rheumatology 2019;58:vii29–vii39.
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., 2017.
Wang, P., Chen, Y., Songs, S. Y. et al. (2017 ). Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. JAMA Oncology.18; 8:730.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2021 Catarina Almeida, Raquel Chemela
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0.
(CINAHL Ultimate database)
